Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox

Histone lysine demethylases facilitate the activity of oncogenic transcription factors, including possibly MYC. Here we show that multiple histone demethylases influence the viability and poor prognosis of neuroblastoma cells, where MYC is often overexpressed. We also identified the approved small-m...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 77; no. 17; pp. 4626 - 4638
Main Authors Yang, Jun, Milasta, Sandra, Hu, Dongli, AlTahan, Alaa M, Interiano, Rodrigo B, Zhou, Junfang, Davidson, Jesse, Low, Jonathan, Lin, Wenwei, Bao, Ju, Goh, Pollyanna, Nathwani, Amit C, Wang, Ruoning, Wang, Yingdi, Ong, Su Sien, Boyd, Vincent A, Young, Brandon, Das, Sourav, Shelat, Anang, Wu, Yinan, Li, Zhenmei, Zheng, Jie J, Mishra, Ashutosh, Cheng, Yong, Qu, Chunxu, Peng, Junmin, Green, Douglas R, White, Stephen, Guy, R Kiplin, Chen, Taosheng, Davidoff, Andrew M
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research, Inc 01.09.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Histone lysine demethylases facilitate the activity of oncogenic transcription factors, including possibly MYC. Here we show that multiple histone demethylases influence the viability and poor prognosis of neuroblastoma cells, where MYC is often overexpressed. We also identified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demethylase inhibitor. Ciclopirox targeted several histone demethylases, including KDM4B implicated in MYC function. Accordingly, ciclopirox inhibited Myc signaling in parallel with mitochondrial oxidative phosphorylation, resulting in suppression of neuroblastoma cell viability and inhibition of tumor growth associated with an induction of differentiation. Our findings provide new insights into epigenetic regulation of MYC function and suggest a novel pharmacologic basis to target histone demethylases as an indirect MYC-targeting approach for cancer therapy. .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-16-0826